January 24, 2012

Genzyme Announces FDA Approval of Framingham Manufacturing Plant

 

Genzyme Announces FDA Approval of Framingham Manufacturing Plant

Paris, France – January 24, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the Food and Drug Administration (FDA) has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme® (agalsidase beta). This follows the previously announced approval by the European Medicines Agency (EMA) last week.